Merck & Co., Inc. (0QAH.L)
LSE - LSE Delayed price. Currency in EUR
Add to watchlist
At close: 01:41PM GMT
| Previous close | N/A |
| Open | 74.85 |
| Bid | 0.00 x N/A |
| Ask | 0.00 x N/A |
| Day's range | 74.85 - 74.85 |
| 52-week range | 74.85 - 74.85 |
| Volume | |
| Avg. volume | N/A |
| Market cap | N/A |
| Beta (5Y monthly) | 0.42 |
| PE ratio (TTM) | 27.03 |
| EPS (TTM) | 2.77 |
| Earnings date | 02 Feb 2022 - 07 Feb 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Editor's pickYahoo Finance Video
COVID: ‘We need to stop wearing cloth masks and go to N95s for all,’ expert says
Jose Luis Jimenez, University of Colorado at Boulder professor of chemistry and CIRES fellow, joins Yahoo Finance Live to give his expert opinion on where investments in masks and ventilation could aid in lowering COVID transmission rates.
- Business Wire
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) as Adjuvant Treatment for Adult and Pediatric (≥12 Years of Age) Patients With Stage IIB or IIC Melanoma Following Complete Resection
KENILWORTH, N.J., December 03, 2021--FDA Approves KEYTRUDA as Adjuvant Treatment for Adult and Pediatric (Age 12+) Patients With Stage IIB or IIC Melanoma Following Complete Resection
- Yahoo Finance Video
'Investors need to take a longer term perspective' amid market volatility, strategist says
Hennion & Walsh CIO Kevin Mahn joins Yahoo Finance Live to discuss the stock market amid heightened market volatility in recent days.
© 2021 Yahoo. All rights reserved.
